Abstract
Using a test-negative design, we modeled the association between receipt of BNT162b2 KP.2 vaccine and symptomatic COVID-19 among adults testing for SARS-CoV-2 at walk-in clinics in a large US retail pharmacy chain (9/5/2024–12/8/2024). At a median of 37 days post-vaccination, those who received BNT162b2 KP.2 were 48% less likely to test positive.
Competing Interest Statement
Conflict of Interest Disclosures: Dr. Sun and Dr. Lupton reported being employees and stockholders in CVS Health during the conduct of this study. Dr. Rudolph, Mr. Khan, Dr. Puzniak, Dr. Jodar, and Dr. McLaughlin reported being employees and stockholders in Pfizer during the conduct of this study Funding/Support: This study was sponsored by Pfizer. Role of the Funder/Sponsor: The study design was developed by Pfizer and approved by CVS. CVS collected and analyzed the data. Pfizer did not participate in the collection or analysis of data. CVS and Pfizer participated in the interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. Additional Contributions: The authors would like to acknowledge Dr. Jennifer Onwumeh-Okwundu, MD, who is an employee of Pfizer, Inc., and did not receive compensation beyond her salary, for her administrative support of this project.
Clinical Protocols
Funding Statement
This study was funded by Pfizer.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sterling IRB waived ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos